Corcept Therapeutics Investors Warned of Class Action Lawsuit and Important Deadlines

Notice to Corcept Therapeutics Investors

On March 11, 2026, Levi & Korsinsky, LLP issued an alert to investors of Corcept Therapeutics Incorporated, a company listed on NASDAQ under the ticker symbol CORT. This announcement serves as a warning regarding a class action lawsuit concerning alleged securities fraud that affected investors during a defined period between October 31, 2024, and December 30, 2025.

Background of the Case

The lawsuit arises from claims that the company made misleading statements regarding their interactions with the FDA concerning the drug relacorilant, which was intended for treating hypertension associated with hypercortisolism. According to the allegations, there were major concerns from the FDA about the effectiveness assessment of this drug and the potential design flaws in the study called GRACE. More importantly, it is claimed that the company falsely projected confidence in obtaining approval for the drug from the FDA while downplaying significant issues that the FDA had forewarned them about.

Legal Proceedings

Investors who may have sustained financial losses due to these practices are encouraged to take action promptly. The deadline to request the court to appoint a lead plaintiff is April 21, 2026. However, it’s essential to note that being a lead plaintiff is not a requirement to participate in any potential recovery from this lawsuit. If you are a member of the class, compensation may be available at no direct cost to you, which emphasizes the importance of this notification for affected investors.

How to Respond

If you were impacted during the stated period, you can contact Joseph E. Levi, Esq. via email at email protected] or call their office at (212) 363-7500 for assistance. Additionally, further details about the lawsuit can be accessed through the following link: [Corcept Therapeutics Class Action Submission.

Levi & Korsinsky has previously garnered a reputation for assisting shareholders in recovering losses through diligent legal representation. For the past two decades, their teams have successfully facilitated recovery of hundreds of millions of dollars for investors caught in significant financial distress due to alleged corporate malfeasance. The firm has a workforce of over 70 employees dedicated to handling complex securities litigation.

Conclusion

This alert serves a dual purpose: it informs investors about the potential for recovery from losses associated with Corcept Therapeutics, while also fostering awareness of the ongoing legal processes that may impact the shareholder community. Given the seriousness of these allegations, affected investors should not delay in considering their options moving forward.